Sign inSign Up
Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco
120 tablet
Sorafenib
Keep in cold place
Delivering To: —
Overview
Sorafenib 200mg Tablet is used to treat a certain type of cancer (liver cancer, kidney cancer, and thyroid cancer). This tablet belongs to a class of medication known as a tyrosine kinase inhibitor. This medicine helps to stop the growth of cancerous cells. Take this medicine orally.
Kidney cancer, Liver cancer, and Thyroid cancer
Thyroid cancer
Kidney cancer
Liver cancer
Sorafenib 200mg Tablet may cause certain side effects. Make sure to contact your healthcare professional if side effects occur after administration or last longer than usual.
Diarrhea
Abdominal pain
Fatigue
Coughing up blood
Bleeding gums
Nausea
Bloating
Difficulty in breathing
Irregular heartbeat
Pale skin
Seizures Sore throat
Indigestion
Hair loss
Numbness
Take Sorafenib 200mg Tablet orally on an empty stomach once a day. Try not to miss your regular dosing schedule. Take this medicine as prescribed by your medical advisor. Do not crush or chew the tablet. The dose is decided by a medical advisor according to your response to the treatment and your previous medical condition. Regular monitoring of blood pressure is required during treatment with this medicine. Keep yourself hydrated and maintain good nutrition while taking this medicine.
Sorafenat is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenat inhibited the tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon Sorafenat treatment, and increases in tumor apoptosis were observed in models of HCC, RCC, and DTC.
Alcohol
unsafe
It is advisable not to consume alcohol while taking medicine.
Pregnancy
consult your doctor
Do not take Sorafenib 200mg Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not consume Sorafenib 200mg Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
It is advisable not to miss a dose. If you miss a scheduled dose of Sorafenat tablet, contact your doctor immediately.
This medication is used to treat a certain type of cancer (liver cancer, kidney cancer, and thyroid cancer). This tablet belongs to a class of medication known as a tyrosine kinase inhibitor. This medicine helps to stop the growth of cancerous cells.
Those who have squamous cell lung cancer, are allergic to any of its chemicals, or are currently taking carboplatin and paclitaxel are not advised to use Sorafenat 200mg Tablet.
Sorafenat 200mg Tablet works by blocking the action of a protein that signals the cancer cells to multiply. This helps in slowing down the growth of cancer cells.
Some common side effects of this medicine are nausea, irregular heartbeat, seizures, pale skin, abdominal pain, bleeding, diarrhea, and fatigue.
This medicine may decrease your ability to drive or affect your vision. Do not drive if any symptoms occur.
Yes, people with diabetes can safely consume 200 mg tablets of sorafenat. Only take it after consulting a physician, though, as they may alter the dosage depending on the patient's health.
Take this medicine on an empty stomach orally once a day or as advised by the doctor.
Pharmacokinetic and pharmacodynamic characteristics of sorafenib 200 mg film‑coated tablets (sorafenat). (n.d.). Absorption, metabolism, and elimination profiles. medthority.com and PMC article summary.
Study 100554 (SHARP trial) and Study 11849: sorafenib versus placebo in hepatocellular carcinoma and renal cell carcinoma. (n.d.). Summary of product characteristics and pivotal trial data publications. medicines.org.uk [SmPC & EMA summary].
Suk, F. M., Wu, C. Y., Fang, C. C., Chen, T. L., & Liao, Y. J. (2023, August 9). β‑HB treatment reverses sorafenib resistance by shifting glycolysis‑lactate metabolism in HCC. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2023.115293
TARGET Phase III trial: sorafenib in advanced renal cell carcinoma. (n.d.). Trial summary data reporting median PFS, OS, and hazard ratios. medicines.org.uk [SmPC & EMA summary].
Natco
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.